Appili Therapeutics (OTCMKTS:APLIF), Inc., headquartered in Halifax, Nova Scotia, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel anti-infective and immuno-oncology therapeutics. Established in 2008 as a spinout from Acadia Pharmaceuticals, Appili has built a diversified pipeline of small-molecule drug candidates aimed at addressing unmet medical needs in antibiotic-resistant infections and rare genetic diseases.
The company’s lead program, ATI-2123, is a reformulated piperacillin-tazobactam designed to treat serious hospital-acquired and ventilator-associated pneumonias caused by multidrug-resistant Gram-negative bacteria. ATI-2123 has advanced into Phase 2 clinical trials, where it has shown potential for enhanced tissue penetration and stability compared to current standard therapies. In parallel, Appili is advancing ATI-1701, a potentiator of aminoglycoside antibiotics for multidrug-resistant tuberculosis, and ATI-1501, an adjunctive therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis patients.
Appili operates research and development facilities in Canada, with a strategic presence in Boston, Massachusetts, to support U.S. regulatory activities and collaborations. The company partners with academic centers and contract research organizations across North America and Europe to optimize its clinical and preclinical programs. Leadership is headed by President and CEO Steve Shalita, a veteran of the biotechnology industry, alongside Chief Scientific Officer Brock Novick, Ph.D., whose expertise in microbiology underpins Appili’s scientific direction.
Since its inception, Appili has secured funding through public offerings on the OTC Markets and strategic partnerships, enabling steady progression of its development pipeline. The company’s mission is to provide innovative therapies that combat emerging infectious diseases and improve global patient outcomes. By focusing on high-barrier-to-entry indications and leveraging proprietary formulation technology, Appili Therapeutics aims to establish itself as a leader in the anti-infective and immuno-oncology arenas.
